731810-56-3

Usage

Uses

Used in Pharmaceutical Synthesis:
METHYL 6-N-BOC-AMINOINDOLE-4-CARBOXYLATE is used as an intermediate in the synthesis of pharmaceuticals for its ability to control reactivity and selectivity in chemical reactions. The BOC protecting group allows for the synthesis of complex molecules with specific functional groups, facilitating the development of new drugs with improved efficacy and safety profiles.
Used in Agrochemical Synthesis:
In the agrochemical industry, METHYL 6-N-BOC-AMINOINDOLE-4-CARBOXYLATE is used as a key intermediate in the production of various agrochemicals. Its versatility in organic synthesis enables the development of novel compounds with enhanced pesticidal, herbicidal, or fungicidal properties, contributing to more effective and sustainable agricultural practices.
Used in Organic Synthesis:
METHYL 6-N-BOC-AMINOINDOLE-4-CARBOXYLATE is utilized as a versatile building block in organic synthesis, allowing for the creation of a wide range of organic compounds. Its unique structural features, including the BOC protecting group and the methyl ester functionality, enable the synthesis of complex molecules with diverse applications in various industries, such as materials science, chemical research, and specialty chemicals.

InChI:InChI=1/C15H18N2O4/c1-15(2,3)21-14(19)17-9-7-11(13(18)20-4)10-5-6-16-12(10)8-9/h5-8,16H,1-4H3,(H,17,19)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 103956-00-9 methyl 6-amino-1H-indole-4-carboxylate 
• 731810-08-5 6-amino-1H-indole-4-carboxylic acid methyl ester hydrochloride 

Downstream Products

• 948015-63-2 6-((tert-butoxycarbonyl)amino)-1H-indole-4-carboxylic acid 

Relevant academic research and scientific papers

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

2-AMINOQUINAZOLINE DERIVATIVE

An object of the present invention is to provide compounds which are useful as protein kinase inhibitors. Disclosed is a 2-aminoquinazoline derivative represented by the following formula (I): wherein R1 represents a lower alkyl group which may be substituted with a halogen atom, or a halogen atom; R2 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a halogen atom, a hydroxyl group, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted amino group, a substituted or unsubstituted acylamino group, a carboxyl group, a lower alkoxycarbonyl group, a carbamoyl group, or a substituted or unsubstituted lower alkylureido group; and X, Y and Z each independently represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a halogen atom, a hydroxyl group, a carboxyl group, a lower alkoxycarbonyl group, a cyano group, a carbamoyl group, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted amino group, a substituted or unsubstituted lower alkoxycarbonylamino group, a substituted or unsubstituted lower alkylaminocarbonyl group, a lower alkylsulfonylamino group, a substituted or unsubstituted lower alkylureido group, or a substituted or unsubstituted acylamino group, or X and Y may be combined to form a 5- to 6-membered ring forming a bicyclic fused ring, wherein the 5- to 6-membered ring may optionally have a substituent, provided that when X and Y are not combined to form a fused ring, R2 represents a hydrogen atom and, when X and Y are combined to form a fused ring, a saturated or unsaturated, bicyclic alicyclic or heterocyclic fused ring can be formed.

POLYMORPHIC FORMS OF (2R,Z)-2-AMINO-2-CYCLOHEXYL-N-(5-(1-METHYL-1H-PYRAZOL-4ΥL)-1-OXO-2,6-DIHYDRO-1H-[1,2]DIAZEPINO[4,5,6-CD]INDOL-8-YL)ACETAMIDE

The present invention relates to novel polymorphic forms and amorphous form of (2R,Z)-2-amino-2-cyclohexyl-N-(5-(1-methyl-1H-pyrazol-4-yl)-1-oxo-2,6-dihydro-1H-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide, and to processes for their preparation. Such poly